Mavorixafor ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 65 | 原発性免疫不全症候群 | 12 |
65. 原発性免疫不全症候群
臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-001153-10-GB (EUCTR) | 21/12/2020 | 29/06/2020 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Phase 3 | United States;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 2 | EUCTR2019-001153-10-DE (EUCTR) | 20/10/2020 | 26/03/2020 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 28 | Phase 3 | Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;Germany;Korea, Republic of;United States;Spain;Turkey;Austria;Israel | ||
| 3 | EUCTR2019-001153-10-AT (EUCTR) | 16/10/2020 | 24/03/2020 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Phase 3 | United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 4 | EUCTR2019-001153-10-NL (EUCTR) | 09/09/2020 | 06/04/2020 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Phase 3 | United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 5 | EUCTR2019-001153-10-PL (EUCTR) | 27/04/2020 | 09/03/2020 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 28 | Phase 3 | United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 6 | EUCTR2019-001153-10-ES (EUCTR) | 02/03/2020 | 02/12/2019 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | Portugal;United States;Spain;Turkey;Austria;Israel;Italy;United Kingdom;France;Hungary;European Union;Canada;Poland;Belgium;Romania;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 7 | EUCTR2019-001153-10-IT (EUCTR) | 18/02/2020 | 17/06/2021 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10020986;Term: Hypogammaglobulinemia, unspecified;System Organ Class: 100000004870;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: [X4P-001] INN or Proposed INN: Mavorixafor | X4 PHARMACEUTICALS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Phase 3 | United States;Spain;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 8 | EUCTR2019-001153-10-FR (EUCTR) | 05/02/2020 | 16/10/2019 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10010512;Term: Congenital immunodeficiency;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Phase 3 | United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;European Union;Canada;Belgium;Poland;Romania;Australia;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 9 | EUCTR2019-001153-10-HU (EUCTR) | 08/01/2020 | 08/11/2019 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 28 | Phase 3 | United States;Portugal;Spain;Turkey;Austria;Israel;United Kingdom;Italy;France;Hungary;European Union;Canada;Poland;Belgium;Romania;Australia;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 10 | EUCTR2019-001153-10-DK (EUCTR) | 16/12/2019 | 21/10/2019 | A treatment study in patients with WHIM Syndrome. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension - A treatment study in patients with WHIM Syndrome. | WHIM Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: Mavorixafor Product Code: X4P-001 INN or Proposed INN: Mavorixafor | X4 Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 28 | Phase 3 | United States;Spain;Austria;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Poland;Denmark;Australia;Germany;Netherlands;Korea, Republic of | ||
| 11 | NCT03995108 (ClinicalTrials.gov) | October 17, 2019 | 19/6/2019 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension | WHIM Syndrome | Drug: Mavorixafor;Drug: Placebo | X4 Pharmaceuticals | NULL | Active, not recruiting | 12 Years | N/A | All | 28 | Phase 3 | United States;Australia;Austria;Denmark;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey |
| 12 | NCT03005327 (ClinicalTrials.gov) | December 2016 | 20/12/2016 | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | A Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients With WHIM Syndrome | WHIM Syndrome | Drug: X4P-001 | X4 Pharmaceuticals | NULL | Active, not recruiting | 18 Years | N/A | All | 15 | Phase 2 | United States;Australia |